Sabra Health Care REIT Stock Price Target and Analyst Ratings (NASDAQ:SBRA)

Analyst Price Target for SBRA

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$17.54

▲ +0.91% Upside Potential

This price target is based on 12 analysts offering 12 month price targets for Sabra Health Care REIT in the last 3 months. The average price target is $17.54, with a high forecast of $25.00 and a low forecast of $14.00. The average price target represents a 0.91% upside from the last price of $17.38.

Hold

The current consensus among 12 contributing investment analysts is to hold stock in Sabra Health Care REIT. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
0 buy ratings
5 hold ratings
1 sell ratings

Ratings as of

8/4/2019

0 strong buy ratings
2 buy ratings
5 hold ratings
1 sell ratings

Ratings as of

11/2/2019

0 strong buy ratings
2 buy ratings
3 hold ratings
1 sell ratings

Ratings as of

1/31/2020

0 strong buy ratings
3 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

4/30/2020

0 strong buy ratings
3 buy ratings
5 hold ratings
1 sell ratings

Ratings as of

7/29/2020

0 strong buy ratings
3 buy ratings
6 hold ratings
1 sell ratings

Ratings as of

10/27/2020

0 strong buy ratings
3 buy ratings
6 hold ratings
1 sell ratings

Ratings as of

12/26/2020

0 strong buy ratings
4 buy ratings
7 hold ratings
1 sell ratings

Ratings as of

1/25/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
1/13/2021	Mizuho	Downgrade	Buy ➝ Neutral	$18.00	Low	i
1/13/2021	Jefferies Financial Group	Upgrade	Hold ➝ Buy	$17.00 ➝ $20.00	Low	i
1/7/2021	BMO Capital Markets	Upgrade	Underperform ➝ Market Perform	$19.00	Low	i
12/15/2020	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Boost Price Target		$14.00 ➝ $17.00	Medium	i
12/15/2020	Smith Barney Citigroup	Boost Price Target		$14.00 ➝ $17.00	Medium	i
12/3/2020	JMP Securities	Upgrade	Market Perform ➝ Outperform	$24.00	Medium	i
10/2/2020	Mizuho	Boost Price Target	Buy	$14.00 ➝ $16.00	High	i
9/1/2020	Stifel Nicolaus	Reiterated Rating	Hold	$15.00	High	i
7/2/2020	Citigroup	Boost Price Target	Neutral	$10.00 ➝ $14.00	Low	i
6/23/2020	Scotiabank	Upgrade	Sector Underperform ➝ Sector Perform	$12.00 ➝ $15.00	Medium	i
6/22/2020	Wells Fargo & Company	Boost Price Target	Equal Weight	$13.00 ➝ $14.00	Low	i
6/8/2020	JMP Securities	Initiated Coverage	Market Perform		Low	i
5/18/2020	Berenberg Bank	Upgrade	Hold ➝ Buy	$15.00	High	i
4/23/2020	SunTrust Banks	Reiterated Rating	Hold	$15.00	Medium	i
4/7/2020	Citigroup	Lower Price Target	Neutral	$20.00 ➝ $10.00	High	i Rating by Nicholas Joseph at Citigroup Inc.
3/26/2020	Wells Fargo & Company	Lower Price Target	Equal Weight	$22.00 ➝ $10.50	Medium	i
3/23/2020	Bank of America	Downgrade	Neutral ➝ Underperform		Medium	i
2/26/2020	Mizuho	Upgrade	Neutral ➝ Buy	$22.00	Low	i
2/6/2020	Barclays	Lower Price Target	Overweight	$26.00 ➝ $25.00	Low	i
2/5/2020	Berenberg Bank	Initiated Coverage	Hold	$22.00	Medium	i
12/19/2019	Mizuho	Initiated Coverage	Neutral	$22.00	Medium	i
12/18/2019	Citigroup	Upgrade	Sell ➝ Neutral	$20.00	High	i
10/14/2019	Bank of America	Initiated Coverage	Neutral		Low	i
9/27/2019	JMP Securities	Boost Price Target	Market Outperform	$22.00 ➝ $23.00	Low	i
9/23/2019	Citigroup	Downgrade	Neutral ➝ Sell	$18.00 ➝ $20.00	Low	i
9/3/2019	Barclays	Initiated Coverage	Overweight	$24.00	High	i
2/26/2019	BMO Capital Markets	Downgrade	Market Perform ➝ Underperform		Medium	i
1/14/2019	BMO Capital Markets	Reiterated Rating	Hold	$17.00	Medium	i
12/18/2018	SunTrust Banks	Downgrade	Buy ➝ Hold		Medium	i
11/20/2018	Citigroup	Set Price Target	Hold	$18.00	Low	i Rating by Michael Bilerman at Citigroup Inc.
11/16/2018	Bank of America	Downgrade	Neutral ➝ Underperform	$23.00 ➝ $21.00	Medium	i
11/16/2018	Raymond James	Downgrade	Outperform ➝ Market Perform		Medium	i Rating by Jonathan Hughes at Raymond James
11/13/2018	Mizuho	Downgrade	Buy ➝ Neutral	$21.00	Medium	i
9/18/2018	BMO Capital Markets	Initiated Coverage	Market Perform	$24.00	Medium	i
8/17/2018	Raymond James	Boost Price Target	Outperform ➝ Buy	$22.00 ➝ $24.00	Medium	i Rating by Jonathan Hughes at Raymond James
8/13/2018	Mizuho	Reiterated Rating	Buy	$26.00	Low	i Rating by Richard Anderson at Mizuho
7/18/2018	Jefferies Financial Group	Reiterated Rating	$21.91	$22.00	Low	i
6/11/2018	JMP Securities	Boost Price Target	Market Outperform ➝ Market Outperform	$21.00 ➝ $22.00	Low	i
6/4/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$25.00	Medium	i
6/1/2018	Raymond James	Upgrade	Outperform		Low	i Rating by Jonathan Hughes at Raymond James
5/21/2018	Raymond James	Upgrade	Market Perform ➝ Outperform		High	i Rating by Jonathan Hughes at Raymond James
5/14/2018	JMP Securities	Boost Price Target	Outperform ➝ Outperform	$19.00 ➝ $21.00	Low	i
5/9/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$25.00	High	i
3/26/2018	Bank of America	Upgrade	Underperform ➝ Neutral	$20.00	Medium	i
3/20/2018	Wells Fargo & Company	Lower Price Target	Market Perform ➝ Market Perform	$24.00 ➝ $19.00	Medium	i
3/14/2018	Mizuho	Upgrade	Neutral ➝ Buy	$24.00	Low	i Rating by Richard Anderson at Mizuho
2/23/2018	Mizuho	Set Price Target	Hold	$18.00	Low	i Rating by Richard Anderson at Mizuho
2/22/2018	Stifel Nicolaus	Reiterated Rating	Hold ➝ Hold	$22.00 ➝ $21.00	Medium	i
1/22/2018	SunTrust Banks	Set Price Target	Buy	$22.00	Low	i Rating by Eric Fleming at SunTrust Banks, Inc.
12/21/2017	Jefferies Financial Group	Reiterated Rating	Buy ➝ Hold		Low	i
12/13/2017	Raymond James	Reiterated Rating	Hold		Medium	i Rating by Jonathan Hughes at Raymond James
11/3/2017	SunTrust Banks	Reiterated Rating	Buy	$25.00	N/A	i
11/3/2017	Stifel Nicolaus	Reiterated Rating	Hold	$22.00	N/A	i
10/9/2017	SunTrust Banks	Reiterated Rating	Buy	$30.00	N/A	i
10/4/2017	Mizuho	Reiterated Rating	Hold	$23.00	Low	i
9/28/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$30.00	Low	i
9/27/2017	Jefferies Financial Group	Reiterated Rating	Buy	$25.00 ➝ $24.00	Low	i
9/25/2017	Capital One Financial	Initiated Coverage	Equal Weight	$24.00	Low	i Rating by D. Bernstein at Capital One Financial Co.
9/11/2017	Mizuho	Upgrade	Underperform ➝ Neutral	$23.00 ➝ $24.00	Medium	i
9/8/2017	Bank of America	Boost Price Target	Underperform	$21.00 ➝ $22.00	Low	i
9/8/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$30.00	Medium	i
9/5/2017	JMP Securities	Upgrade	Market Perform ➝ Outperform	$23.00	Low	i
8/15/2017	Jefferies Financial Group	Upgrade	Hold ➝ Buy	$25.00	Medium	i
7/28/2017	Stifel Nicolaus	Reiterated Rating	Hold	$26.00	Medium	i
7/10/2017	Mizuho	Downgrade	Neutral ➝ Underperform	$25.00 ➝ $23.00	Low	i
7/9/2017	Jefferies Financial Group	Reiterated Rating	Hold	$28.00 ➝ $25.00	Low	i
6/28/2017	Mizuho	Reiterated Rating	Neutral		Low	i
5/12/2017	Jefferies Financial Group	Reiterated Rating	Hold	$28.00	Low	i
5/9/2017	Canaccord Genuity	Reiterated Rating	Hold	$26.00	Low	i
5/8/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$30.00	High	i
2/28/2017	Cantor Fitzgerald	Boost Price Target	Overweight	$25.00 ➝ $30.00	N/A	i
2/27/2017	Stifel Nicolaus	Boost Price Target	Hold	$24.00 ➝ $26.00	N/A	i
2/27/2017	Mizuho	Reiterated Rating	Neutral ➝ Neutral	$22.00 ➝ $28.00	N/A	i
1/31/2017	Jefferies Financial Group	Reiterated Rating	Hold	$25.00	N/A	i
12/28/2016	JMP Securities	Reiterated Rating	Market Perform		N/A	i
10/23/2016	Jefferies Financial Group	Reiterated Rating	Hold	$25.00	N/A	i
10/10/2016	Mizuho	Reiterated Rating	Neutral	$23.00	N/A	i Rating by Richard Anderson at Mizuho
9/9/2016	JMP Securities	Reiterated Rating	Hold		N/A	i
9/9/2016	Cantor Fitzgerald	Reiterated Rating	Buy		N/A	i Rating by Joseph France at Cantor Fitzgerald
8/25/2016	BTIG Research	Initiated Coverage	Neutral		N/A	i
8/19/2016	Cantor Fitzgerald	Reiterated Rating	Buy		N/A	i Rating by Joseph France at Cantor Fitzgerald
8/17/2016	Citigroup	Boost Price Target	Neutral	$22.00 ➝ $24.00	N/A	i
7/25/2016	Bank of America	Downgrade	Neutral ➝ Underperform		N/A	i
7/7/2016	Citigroup	Lower Price Target	Neutral	$24.00 ➝ $22.00	N/A	i
6/23/2016	Cantor Fitzgerald	Initiated Coverage	Buy	$28.00	N/A	i Rating by Joseph France at Cantor Fitzgerald
6/1/2016	SunTrust Banks	Upgrade	Neutral ➝ Buy	$25.00	N/A	i
5/31/2016	Canaccord Genuity	Reiterated Rating	Hold	$23.00	N/A	i Rating by Paul Morgan at Canaccord Genuity
5/19/2016	Mizuho	Downgrade	Buy ➝ Neutral	$25.00 ➝ $20.00	N/A	i
5/2/2016	Canaccord Genuity	Reiterated Rating	Hold		N/A	i Rating by Paul Morgan at Canaccord Genuity
4/12/2016	Raymond James	Downgrade	Outperform ➝ Market Perform		N/A	i
4/7/2016	Jefferies Financial Group	Boost Price Target	Hold	$21.00	N/A	i
4/6/2016	Canaccord Genuity	Reiterated Rating	Hold		N/A	i Rating by Paul Morgan at Canaccord Genuity
2/23/2016	Barclays	Lower Price Target	Overweight	$23.00 ➝ $21.00	N/A	i
2/23/2016	(FBRC)	Reiterated Rating	Outperform	$26.00 ➝ $24.00	N/A	i Rating by Daniel Altscher at (FBRC)
2/14/2016	(FBRC)	Reiterated Rating	Outperform	$26.00	N/A	i Rating by Daniel Altscher at (FBRC)
1/29/2016	(FBRC)	Reiterated Rating	Outperform	$26.00	N/A	i Rating by Daniel Altscher at (FBRC)

(Data available from 1/26/2016 forward)

As of September 30, 2020, Sabra's investment portfolio included 425 real estate properties held for investment (consisting of (i) 287 Skilled Nursing/Transitional Care facilities, (ii) 64 Senior Housing communities (ÂSenior Housing - LeasedÂ), (iii) 47 Senior Housing communities operated by third-party property managers pursuant to property management agreements (ÂSenior Housing - ManagedÂ) and (iv) 27 Specialty Hospitals and Other facilities), one asset held for sale, one investment in a direct financing lease, 19 investments in loans receivable (consisting of (i) one mortgage loan, (ii) one construction loan and (iii) 17 other loans), six preferred equity investments and one investment in an unconsolidated joint venture that owns 158 Senior Housing - Managed communities. As of September 30, 2020, Sabra's real estate properties held for investment included 42,378 beds/units and its unconsolidated joint venture included 7,056 beds/units, spread across the United States and Canada.

Today's Range

Now: $17.38

$16.90

$17.47

50 Day Range

MA: $17.44

$16.84

$17.97

52 Week Range

Now: $17.38

$5.55

$22.55

Volume

1,511,273 shs

Average Volume

1,319,712 shs

Market Capitalization

$3.60 billion

P/E Ratio

25.19

Dividend Yield

6.94%

Beta

1.49

Frequently Asked Questions

What sell-side analysts currently cover shares of Sabra Health Care REIT?

The following Wall Street research analysts have issued stock ratings on Sabra Health Care REIT in the last twelve months: Bank of America Co., Barclays PLC, Berenberg Bank, BMO Capital Markets, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Jefferies Financial Group Inc., JMP Securities, Mizuho, Scotiabank, Smith Barney Citigroup, Stifel Nicolaus, SunTrust Banks, Inc., TheStreet, Wells Fargo & Company, and Zacks Investment Research.

What is the current price target for Sabra Health Care REIT?

13 Wall Street analysts have set twelve-month price targets for Sabra Health Care REIT in the last year. Their average twelve-month price target is $17.54, suggesting a possible upside of 1.1%. Barclays PLC has the highest price target set, predicting SBRA will reach $25.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $14.00 for Sabra Health Care REIT in the next year.

What is the current consensus analyst rating for Sabra Health Care REIT?

Sabra Health Care REIT currently has 1 sell rating, 7 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in SBRA, but not buy more shares or sell existing shares.

What other companies compete with Sabra Health Care REIT?

Other companies that are similar to Sabra Health Care REIT include American Tower, Public Storage, Welltower, Weyerhaeuser, Ventas, Extra Space Storage, HCP, Medical Properties Trust, Omega Healthcare Investors, CubeSmart, Life Storage, Rayonier, Healthcare Realty Trust, Ryman Hospitality Properties and PotlatchDeltic.

How do I contact Sabra Health Care REIT's investor relations team?

Sabra Health Care REIT's physical mailing address is 18500 VON KARMAN AVENUE SUITE 550, IRVINE CA, 92612. The real estate investment trust's listed phone number is 888-393-8248 and its investor relations email address is [email protected] The official website for Sabra Health Care REIT is www.sabrahealth.com.

NASDAQ:SBRA - Sabra Health Care REIT Stock Price Target and Predictions

Analyst Price Target for SBRA

Past Monthly Recommendations

Latest Recommendations

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Sabra Health Care REIT?

What is the current price target for Sabra Health Care REIT?

What is the current consensus analyst rating for Sabra Health Care REIT?

What other companies compete with Sabra Health Care REIT?

How do I contact Sabra Health Care REIT's investor relations team?